Snakebite	O
envenomation	O
can	O
cause	O
local	O
tissue	O
damage	O
,	O
with	O
edema	other-medical
,	O
hemorrhage	other-medical
,	O
myonecrosis	other-medical
,	O
and	O
systemic	other-medical
toxic	other-medical
responses	other-medical
,	O
including	O
organ	O
failure	O
.	O

Flunitrazepam	other-medical
was	O
discovered	O
at	O
Roche	O
as	O
part	O
of	O
the	O
benzodiazepine	O
work	O
led	O
by	O
Leo	O
Sternbach	O
;	O
the	O
patent	O
application	O
was	O
filed	O
in	O
1962	O
and	O
it	O
was	O
first	O
marketed	O
in	O
1974	O
.	O

RLS	O
symptoms	O
decrease	O
with	O
the	O
use	O
of	O
drugs	O
that	O
stimulate	O
dopamine	O
receptors	O
and	O
increase	O
dopamine	O
levels	O
,	O
such	O
as	O
dopamine	other-medical
agonists	other-medical
.	O

A	O
Cochrane	O
review	O
concluded	O
that	O
there	O
is	O
no	O
credible	O
link	O
between	O
the	O
MMR	other-medical
vaccine	other-medical
and	O
autism	O
,	O
that	O
MMR	other-medical
has	O
prevented	O
diseases	O
that	O
still	O
carry	O
a	O
heavy	O
burden	O
of	O
death	O
and	O
complications	O
,	O
that	O
the	O
lack	O
of	O
confidence	O
in	O
MMR	other-medical
has	O
damaged	O
public	O
health	O
,	O
and	O
that	O
the	O
design	O
and	O
reporting	O
of	O
safety	O
outcomes	O
in	O
MMR	other-medical
vaccine	other-medical
studies	O
are	O
largely	O
inadequate	O
.	O

It	O
tends	O
to	O
be	O
slightly	O
activating/stimulating	O
rather	O
than	O
sedating	O
,	O
unlike	O
most	O
others	O
TCAs	other-medical
.	O

Applied	other-medical
Behavior	other-medical
Analysis	other-medical
is	O
the	O
only	O
empirically	O
proven	O
method	O
of	O
treatment	O
.	O

Loratadine	other-medical
,	O
another	O
non-sedating	O
antihistamine	O
,	O
is	O
the	O
prodrug	O
of	O
desloratadine	other-medical
,	O
which	O
is	O
largely	O
responsible	O
for	O
the	O
antihistaminergic	O
effects	O
of	O
the	O
parent	O
compound	O
.	O

The	O
raceday	O
ban	O
on	O
Lasix	other-medical
would	O
eventually	O
be	O
removed	O
for	O
the	O
2014	O
event	O
.	O

They	O
and	O
their	O
parents	O
sued	O
Merrell	O
Dow	O
Pharmaceuticals	O
Inc	O
.	O
,	O
a	O
subsidiary	O
of	O
Dow	O
Chemical	O
Company	O
,	O
in	O
a	O
California	O
District	O
Court	O
,	O
claiming	O
that	O
the	O
drug	O
Bendectin	other-medical
had	O
caused	O
the	O
birth	O
defects	O
.	O

Atropine	other-medical
blocks	O
acetylcholine	O
from	O
binding	O
with	O
muscarinic	O
receptors	O
,	O
which	O
reduces	O
the	O
pesticide	O
's	O
impact	O
.	O

Taking	O
it	O
with	O
vitamin	other-medical
C	other-medical
has	O
been	O
investigated	O
as	O
a	O
method	O
of	O
protecting	O
the	O
stomach	O
lining	O
.	O

The	O
Demon	O
Under	O
the	O
Microscope	O
:	O
From	O
Battlefield	O
Hospitals	O
to	O
Nazi	O
Labs	O
,	O
One	O
Doctor	O
's	O
Heroic	O
Search	O
for	O
the	O
World	O
's	O
First	O
Miracle	O
Drug	O
is	O
a	O
2006	O
nonfiction	O
book	O
about	O
the	O
discovery	O
of	O
Prontosil	other-medical
,	O
the	O
first	O
commercially	O
available	O
antibacterial	other-medical
antibiotic	other-medical
and	O
sulfanilamide	other-medical
,	O
the	O
second	O
commercial	O
antibiotic	other-medical
.	O

Liraglutide	other-medical
,	O
sold	O
under	O
the	O
brand	O
name	O
Victoza	O
among	O
others	O
,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
diabetes	O
mellitus	O
type	O
2	O
and	O
obesity	O
.	O

Rates	O
of	O
sexual	O
dysfunction	O
in	O
MDD	O
patients	O
treated	O
with	O
duloxetine	other-medical
vs	O
escitalopram	other-medical
did	O
not	O
differ	O
significantly	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
of	O
treatment	O
,	O
although	O
the	O
trend	O
favored	O
duloxetine	other-medical
(	O
33.3	O
%	O
of	O
duloxetine	other-medical
patients	O
experienced	O
sexual	O
side	O
effects	O
compared	O
to	O
43.6	O
%	O
of	O
those	O
receiving	O
escitalopram	other-medical
and	O
25	O
%	O
of	O
those	O
receiving	O
placebo	other-medical
)	O
.	O

A	O
meta-analysis	O
of	O
53	O
clinical	O
trials	O
has	O
shown	O
that	O
all	O
triptans	other-medical
are	O
effective	O
for	O
treating	O
migraine	O
at	O
marketed	O
doses	O
and	O
that	O
naratriptan	other-medical
,	O
although	O
less	O
effective	O
than	O
sumatriptan	other-medical
and	O
rizatriptan	other-medical
was	O
more	O
effective	O
than	O
placebo	O
in	O
reducing	O
migraine	O
symptoms	O
at	O
two	O
hours	O
and	O
efficacy	O
was	O
demonstrated	O
in	O
almost	O
two	O
thirds	O
of	O
subjects	O
after	O
four	O
hours	O
of	O
treatment	O
.	O

Natalizumab	other-medical
is	O
considered	O
highly	O
effective	O
in	O
terms	O
of	O
relapse	O
rate	O
reduction	O
and	O
halting	O
disability	O
progression	O
,	O
however	O
,	O
it	O
is	O
considered	O
a	O
second-line	O
treatment	O
because	O
of	O
the	O
risk	O
of	O
adverse	O
side-effects	O
.	O

Trimecaine	other-medical
must	O
not	O
be	O
used	O
at	O
hypersensitivity	O
on	O
amide	other-medical
anesthetics	other-medical
,	O
hypervolemia	O
,	O
hypotension	O
,	O
cardial	O
conduction	O
defects	O
,	O
asystole	O
,	O
cardiogenic	O
shock	O
and	O
malignant	O
hyperthermia	O
in	O
anamnesis	O
.	O

On	O
June	O
30	O
,	O
2009	O
,	O
an	O
FDA	O
advisory	O
panel	O
recommended	O
that	O
Vicodin	other-medical
and	O
another	O
painkiller	O
,	O
Percocet	other-medical
,	O
be	O
removed	O
from	O
the	O
market	O
because	O
they	O
have	O
allegedly	O
caused	O
over	O
400	O
deaths	O
a	O
year	O
.	O

A	O
solution	O
of	O
1	O
%	O
potassium	O
permanganate	O
dissolved	O
in	O
hot	O
water	O
is	O
an	O
alternative	O
to	O
antifungal	other-medical
drugs	other-medical
.	O

Nodular	O
vasculitis	O
is	O
a	O
skin	O
condition	O
characterized	O
by	O
crops	O
of	O
small	O
,	O
tender	O
,	O
erythematous	other-medical
nodules	other-medical
on	O
the	O
legs	O
,	O
mostly	O
on	O
the	O
calves	O
and	O
shins	O
.	O

Pixantrone	other-medical
also	O
reduces	O
the	O
severity	O
of	O
experimental	O
autoimmune	O
myasthenia	O
gravis	O
in	O
Lewis	O
rats	O
,	O
and	O
in	O
vitro	O
cell	O
viability	O
experiments	O
indicated	O
that	O
Pixantrone	other-medical
significantly	O
reduces	O
amyloid	O
beta	O
(	O
A	O
beta	O
(	O
1-42	O
)	O
)	O
neurotoxicity	O
,	O
a	O
mechanism	O
implicated	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Testosterone	other-medical
enanthate	other-medical
can	O
also	O
lead	O
to	O
an	O
increase	O
in	O
igf-1	O
and	O
igf-bp	O
.	O

Current	O
advances	O
in	O
further	O
treatments	O
include	O
evaluations	O
of	O
triazoles	O
such	O
as	O
itraconazole	other-medical
and	O
fluconazole	other-medical
``	O
as	O
therapeutic	O
options	O
in	O
ophthalmic	O
mycoses	O
.	O
''	O

Chemotherapy	other-medical
for	O
ALL	O
consists	O
of	O
three	O
phases	O
:	O
remission	O
induction	O
,	O
intensification	O
,	O
and	O
maintenance	O
therapy	O
.	O

Metronidazole	other-medical
began	O
to	O
be	O
commercially	O
used	O
in	O
1960	O
in	O
France	O
.	O

Triptans	other-medical
are	O
therefore	O
often	O
preferred	O
treatment	O
in	O
migraine	O
.	O

The	O
FDA	O
approved	O
reslizumab	O
(	O
US	O
trade	O
name	O
Cinqair	other-medical
)	O
for	O
use	O
with	O
other	O
asthma	other-medical
medicines	other-medical
for	O
the	O
maintenance	O
treatment	O
of	O
severe	O
asthma	O
in	O
patients	O
aged	O
18	O
years	O
and	O
older	O
on	O
23	O
March	O
2016	O
.	O

The	O
increased	O
iron	O
stores	O
in	O
the	O
organs	O
involved	O
,	O
especially	O
in	O
the	O
liver	O
and	O
pancreas	O
,	O
result	O
in	O
characteristic	O
findings	O
on	O
unenhanced	O
CT	other-medical
and	O
a	O
decreased	O
signal	O
intensity	O
in	O
MRI	other-medical
scans	O
.	O

This	O
meant	O
that	O
in	O
contrast	O
to	O
flumazenil	other-medical
,	O
which	O
is	O
ineffective	O
at	O
treating	O
alcohol	O
overdoses	O
,	O
Ro15-4513	other-medical
showed	O
potential	O
as	O
a	O
useful	O
alcohol	O
antidote	O
.	O

Second-line	O
therapy	O
for	O
adults	O
is	O
phenytoin	other-medical
or	O
fosphenytoin	other-medical
and	O
phenobarbital	other-medical
for	O
children	O
.	O

The	O
efficacy	O
of	O
fluoxetine	other-medical
in	O
the	O
treatment	O
of	O
panic	O
disorder	O
was	O
demonstrated	O
in	O
two	O
12-week	O
randomized	O
multicenter	O
phase	O
III	O
clinical	O
trials	O
that	O
enrolled	O
patients	O
diagnosed	O
with	O
panic	O
disorder	O
,	O
with	O
or	O
without	O
agoraphobia	O
.	O

But	O
there	O
is	O
also	O
a	O
genetic	O
connection	O
of	O
STPD	O
to	O
mood	other-medical
disorders	other-medical
and	O
depression	O
in	O
particular	O
.	O

Though	O
slightly	O
less	O
potent	O
,	O
artesunate	other-medical
is	O
also	O
useful	O
in	O
human	O
fasciolosis	O
.	O

Cryotherapy	other-medical
,	O
sometimes	O
known	O
as	O
cold	O
therapy	O
,	O
is	O
the	O
local	O
or	O
general	O
use	O
of	O
low	O
temperatures	O
in	O
medical	O
therapy	O
.	O

Emodepside	other-medical
is	O
an	O
anthelmintic	O
drug	O
that	O
is	O
effective	O
against	O
a	O
number	O
of	O
gastrointestinal	O
nematodes	O
,	O
is	O
licensed	O
for	O
use	O
in	O
cats	O
and	O
belongs	O
to	O
the	O
class	O
of	O
drugs	O
known	O
as	O
the	O
``	O
octadepsipeptides	other-medical
``	O
,	O
a	O
relatively	O
new	O
class	O
of	O
anthelmintic	O
(	O
research	O
into	O
these	O
compounds	O
began	O
in	O
the	O
early	O
1990s	O
)	O
,	O
which	O
are	O
suspected	O
to	O
achieve	O
their	O
anti-parasitic	other-medical
effect	O
by	O
a	O
novel	O
mechanism	O
of	O
action	O
due	O
to	O
their	O
ability	O
to	O
kill	O
nematodes	O
resistant	O
to	O
other	O
anthelmintics	other-medical
.	O

Cambodia	O
remains	O
a	O
major	O
supplier	O
of	O
cannabis	other-medical
to	O
countries	O
in	O
East	O
and	O
Southeast	O
Asia	O
and	O
other	O
parts	O
of	O
the	O
world	O
.	O

Diphenhydramine	O
is	O
the	O
primary	O
constituent	O
of	O
dimenhydrinate	other-medical
and	O
dictates	O
the	O
primary	O
effect	O
.	O

Proton-pump	O
inhibitors	O
such	O
as	O
omeprazole	O
and	O
the	O
anticonvulsant	O
valproate	O
have	O
been	O
found	O
to	O
increase	O
the	O
plasma	O
concentrations	O
of	O
methotrexate	O
,	O
as	O
have	O
nephrotoxic	O
agents	O
such	O
as	O
cisplatin	other-medical
,	O
the	O
GI	other-medical
drug	other-medical
colestyramine	other-medical
,	O
and	O
dantrolene	other-medical
.	O

In	O
2020	O
,	O
Baszucki	O
funded	O
a	O
study	O
on	O
the	O
effect	O
of	O
Hydroxychloroquine	other-medical
on	O
COVID-19	O
,	O
which	O
showed	O
no	O
evidence	O
of	O
it	O
preventing	O
or	O
treating	O
the	O
virus	O
.	O

However	O
,	O
ketoconazole	other-medical
has	O
largely	O
been	O
replaced	O
as	O
a	O
first-line	O
systemic	O
antifungal	other-medical
medication	O
by	O
other	O
azole	O
antifungal	O
agents	O
,	O
such	O
as	O
itraconazole	other-medical
,	O
because	O
of	O
ketoconazole	other-medical
's	O
greater	O
toxicity	O
,	O
poorer	O
absorption	O
,	O
and	O
more	O
limited	O
spectrum	O
of	O
activity	O
.	O

His	O
early	O
work	O
focused	O
on	O
premature	O
ejaculation	O
and	O
erectile	O
dysfunction	O
,	O
and	O
he	O
has	O
written	O
on	O
a	O
number	O
of	O
treatment	O
options	O
,	O
including	O
vacuum	other-medical
pumps	other-medical
,	O
injections	other-medical
into	other-medical
the	other-medical
corpus	other-medical
cavernosum	other-medical
of	other-medical
the	other-medical
penis	other-medical
,	O
and	O
Viagra	other-medical
.	O

Thyroid	other-medical
nodules	other-medical
are	O
nodules	other-medical
(	O
raised	O
areas	O
of	O
tissue	O
or	O
fluid	O
)	O
which	O
commonly	O
arise	O
within	O
an	O
otherwise	O
normal	O
thyroid	O
gland	O
.	O

He	O
is	O
the	O
first	O
person	O
to	O
have	O
prepared	O
amphetamine	other-medical
sulfate	other-medical
,	O
although	O
not	O
the	O
amphetamine	other-medical
molecule	O
.	O

Among	O
the	O
first	O
technology	O
to	O
be	O
added	O
to	O
the	O
institute	O
,	O
was	O
equipment	O
for	O
in	O
vivo	O
NMR	other-medical
studies	O
(	O
which	O
nowadays	O
is	O
mainly	O
known	O
as	O
MRI	other-medical
)	O
for	O
animal	O
studies	O
.	O

Petacchi	O
was	O
then	O
absolved	O
by	O
the	O
FCI	O
when	O
they	O
deemed	O
any	O
overuse	O
of	O
Salbutamol	other-medical
as	O
simple	O
human	O
error	O
.	O

Baird	O
,	O
was	O
instrumental	O
in	O
gaining	O
approval	O
for	O
the	O
use	O
of	O
RU-486	other-medical
in	O
the	O
UK	O
as	O
an	O
emergency	O
contraceptive	O
or	O
'morning	O
after	O
pill	O
'	O
.	O

On	O
January	O
25	O
,	O
2011	O
,	O
the	O
FDA	O
approved	O
over-the-counter	O
sales	O
of	O
fexofenadine	other-medical
in	O
the	O
United	O
States	O
,	O
and	O
Sanofi	O
Aventis	O
'	O
version	O
became	O
available	O
on	O
March	O
4	O
,	O
2011	O
.	O

Methicillin	other-medical
-resistant	O
``	O
Staphylococcus	O
aureus	O
``	O
(	O
MRSA	O
)	O
was	O
first	O
detected	O
in	O
Britain	O
in	O
1961	O
,	O
and	O
is	O
now	O
``	O
quite	O
common	O
''	O
in	O
hospitals	O
.	O

Transurethral	other-medical
injection	other-medical
of	O
bulking	O
agents	O
have	O
little	O
role	O
in	O
the	O
management	O
of	O
post-prostatecromy	O
incontinence	O
and	O
there	O
is	O
weak	O
evidence	O
that	O
these	O
agents	O
can	O
offer	O
any	O
improvement	O
.	O

There	O
has	O
never	O
been	O
an	O
adequately	O
large	O
randomized	O
controlled	O
trial	O
to	O
prove	O
definitively	O
that	O
HGH	other-medical
provides	O
significant	O
anti-aging	O
benefits	O
and	O
that	O
there	O
are	O
no	O
significant	O
adverse	O
drug	O
reactions	O
;	O
there	O
have	O
been	O
many	O
small	O
studies	O
which	O
are	O
described	O
below	O
.	O

MDMA	other-medical
tablets	O
are	O
also	O
imported	O
from	O
the	O
Netherlands	O
into	O
China	O
to	O
meet	O
the	O
demand	O
.	O

Compared	O
to	O
other	O
NSAIDs	other-medical
,	O
it	O
may	O
have	O
other	O
side	O
effects	O
such	O
as	O
gastrointestinal	O
bleeding	O
.	O

In	O
2002	O
,	O
Swedish	O
Covenant	O
Hospital	O
completed	O
its	O
hyperbaric	other-medical
oxygen	other-medical
chambers	other-medical
to	O
help	O
wounds	O
heal	O
seven	O
days	O
faster	O
than	O
the	O
national	O
average	O
.	O

``	O
N.	other-medical
gonorrhoeae	other-medical
''	other-medical
is	O
usually	O
isolated	O
on	O
Thayer-Martin	O
agar	O
(	O
or	O
VPN	O
)	O
agar	O
in	O
an	O
environment	O
enriched	O
with	O
3-7	O
%	O
carbon	O
dioxide	O
.	O

A	O
new	O
model	O
has	O
recently	O
surfaced	O
in	O
the	O
literature	O
regarding	O
the	O
HPA	other-medical
axis	other-medical
(	O
structures	O
in	O
the	O
brain	O
that	O
get	O
activated	O
in	O
response	O
to	O
stress	O
)	O
and	O
its	O
involvement	O
with	O
dysthymia	other-medical
(	O
e.g	O
.	O

Court	O
acknowledged	O
that	O
physical	O
efficacy	O
of	O
imatinib	other-medical
mesylate	O
in	O
beta	O
crystalline	O
form	O
is	O
enhanced	O
in	O
comparison	O
to	O
other	O
forms	O
and	O
that	O
the	O
beta	O
crystalline	O
form	O
of	O
imatinib	other-medical
mesylate	O
has	O
30	O
per	O
cent	O
increased	O
bioavailability	O
as	O
compared	O
to	O
imatinib	other-medical
in	O
free	O
base	O
form	O
.	O

RTI-120	O
has	O
a	O
short	O
duration	O
of	O
action	O
,	O
along	O
with	O
other	O
p-	O
methyl	O
substituted	O
phenyltropanes	O
such	O
as	O
RTI-150	O
,	O
RTI-171	O
and	O
RTI-199	O
,	O
giving	O
it	O
a	O
more	O
similar	O
pharmacological	O
profile	O
to	O
cocaine	other-medical
compared	O
to	O
longer	O
acting	O
analogues	O
like	O
RTI-121	O
and	O
RTI-177	O
.	O

Furosemide	other-medical
also	O
can	O
lead	O
to	O
gout	O
caused	O
by	O
hyperuricemia	O
.	O

The	O
most	O
potent	O
aphrodisiacs	other-medical
,	O
according	O
to	O
Levine	O
,	O
are	O
psychological	O
intimacy	O
and	O
voyeurism	O
:	O
``	O
looking	O
at	O
pictures	O
or	O
movies	O
of	O
people	O
engaged	O
in	O
genital	O
or	O
romantic	O
interplay	O
.	O
''	O

Analgecine	other-medical
(	O
brand	O
name	O
AGC	other-medical
)	O
is	O
an	O
analgesic	O
extract	O
that	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
back	other-medical
pain	other-medical
and	O
neuralgia	other-medical
in	O
China	O
.	O

Blockade	O
of	O
COX-1	O
by	O
aspirin	other-medical
apparently	O
results	O
in	O
the	O
upregulation	O
of	O
COX-2	O
as	O
part	O
of	O
a	O
gastric	O
defense	O
and	O
that	O
taking	O
COX-2	O
inhibitors	O
concurrently	O
with	O
aspirin	other-medical
increases	O
the	O
gastric	O
mucosal	O
erosion	O
.	O

Scopolamine	other-medical
(	O
Hyoscine	other-medical
)	O
has	O
anti-emetic	O
activity	O
and	O
is	O
,	O
therefore	O
,	O
used	O
to	O
treat	O
motion	O
sickness	O
.	O

One	O
issue	O
with	O
opioid	other-medical
rotation	O
is	O
that	O
an	O
opioid	other-medical
therapy	O
failure	O
poorly	O
predicts	O
whether	O
other	O
opioids	other-medical
would	O
be	O
effective	O
.	O

Note	O
that	O
treatment	O
of	O
a	O
keloid	other-medical
scar	other-medical
is	O
age	O
dependent	O
:	O
radiotherapy	other-medical
,	O
anti-metabolites	other-medical
and	O
corticosteroids	other-medical
would	O
not	O
be	O
recommended	O
to	O
be	O
used	O
in	O
children	O
,	O
in	O
order	O
to	O
avoid	O
harmful	O
side	O
effects	O
,	O
like	O
growth	other-medical
abnormalities	other-medical
.	O

People	O
taking	O
lithium	other-medical
thus	O
should	O
routinely	O
be	O
assessed	O
for	O
hypothyroidism	O
and	O
treated	O
with	O
synthetic	other-medical
thyroxine	other-medical
if	O
necessary	O
.	O

In	O
some	O
cases	O
,	O
switching	O
from	O
venlafaxine	other-medical
to	O
fluoxetine	other-medical
,	O
a	O
long-acting	O
SSRI	other-medical
,	O
and	O
then	O
tapering	O
off	O
fluoxetine	other-medical
,	O
may	O
be	O
recommended	O
to	O
reduce	O
discontinuation	O
symptoms	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
explore	O
which	O
opioid	other-medical
drugs	O
are	O
most	O
effective	O
in	O
implementing	O
in	O
an	O
opioid	other-medical
rotation	O
,	O
but	O
have	O
so	O
far	O
found	O
no	O
difference	O
in	O
efficacy	O
between	O
opioid	other-medical
drugs	O
like	O
methadone	other-medical
and	O
fentanyl	other-medical
in	O
cancer	O
patients	O
.	O

Rehabilitation	other-medical
robotics	other-medical
is	O
a	O
new	O
frontier	O
for	O
neurological	O
rehabilitation	O
treatments	O
.	O

On	O
15	O
October	O
2010	O
,	O
the	O
multi-national	O
Reckitt	O
Benckiser	O
was	O
fined	O
£	O
10	O
million	O
for	O
rigging	O
the	O
market	O
for	O
Gaviscon	other-medical
following	O
an	O
investigation	O
by	O
Jones	O
and	O
Martin	O
Shankleman	O
.	O

Metronidazole	other-medical
is	O
less	O
effective	O
,	O
but	O
is	O
available	O
in	O
a	O
gel	O
and	O
can	O
be	O
applied	O
twice	O
daily	O
.	O

As	O
with	O
other	O
statins	other-medical
,	O
atorvastatin	other-medical
is	O
a	O
competitive	O
inhibitor	O
of	O
HMG-CoA	O
reductase	O
.	O

Ketamine	other-medical
is	O
a	O
commonly	O
used	O
drug	O
that	O
can	O
cause	O
this	O
type	O
of	O
sedation	O
.	O

Therapeutic	O
doses	O
of	O
fluoxetine	other-medical
have	O
been	O
shown	O
to	O
decrease	O
these	O
neuronal	O
fatigue	O
states	O
by	O
inhibiting	O
vesicle	O
release	O
and	O
thereby	O
preventing	O
synaptic	O
fatigue	O
in	O
hippocampal	O
neurons	O
.	O

GFAP	other-medical
has	O
also	O
been	O
shown	O
to	O
be	O
important	O
in	O
repair	O
after	O
CNS	O
injury	O
.	O

When	O
using	O
over-the-counter	O
drug	O
clotrimazole	other-medical
products	O
,	O
use	O
should	O
be	O
discontinued	O
if	O
condition	O
does	O
not	O
improve	O
after	O
treatment	O
for	O
2	O
weeks	O
for	O
jock	O
itch	O
or	O
after	O
4	O
weeks	O
for	O
athlete	O
's	O
foot	O
or	O
ringworm	O
.	O

To	O
move	O
towards	O
international	O
standards	O
,	O
the	O
Breeders	O
'	O
Cup	O
decided	O
to	O
eliminate	O
the	O
use	O
of	O
Lasix	other-medical
in	O
the	O
Juvenile	O
races	O
,	O
with	O
the	O
intention	O
of	O
extending	O
the	O
ban	O
to	O
other	O
races	O
in	O
subsequent	O
years	O
.	O

An	O
established	O
brain	O
stimulation	O
treatment	O
is	O
electroconvulsive	other-medical
therapy	other-medical
.	O

Sarin	other-medical
acts	O
on	O
acetylcholinesterase	other-medical
by	O
forming	O
a	O
covalent	O
bond	O
with	O
the	O
particular	O
serine	O
residue	O
at	O
the	O
active	O
site	O
.	O

Niimi	O
received	O
an	O
injection	O
of	O
atropine	other-medical
and	O
pralidoxime	other-medical
iodine	other-medical
,	O
saving	O
his	O
life	O
.	O

Metenolone	other-medical
acetate	O
is	O
or	O
has	O
been	O
marketed	O
under	O
a	O
number	O
of	O
brand	O
names	O
including	O
Primobolan	other-medical
,	O
Primobolan	other-medical
S	other-medical
,	O
Primonabol	other-medical
,	O
and	O
Nibal	other-medical
.	O

ADHD	O
,	O
which	O
affects	O
the	O
majority	O
of	O
boys	O
and	O
30	O
%	O
of	O
girls	O
with	O
FXS	O
,	O
is	O
frequently	O
treated	O
using	O
stimulants	other-medical
.	O

Potassium	other-medical
chloride	other-medical
is	O
the	O
last	O
of	O
the	O
three	O
drugs	O
administered	O
and	O
actually	O
causes	O
death	O
.	O

Idiopathic	O
ventricular	O
fibrillation	O
occurs	O
with	O
a	O
reputed	O
incidence	O
of	O
approximately	O
1	O
%	O
of	O
all	O
cases	O
of	O
out-of-hospital	O
arrest	O
,	O
as	O
well	O
as	O
3–9	O
%	O
of	O
the	O
cases	O
of	O
ventricular	O
fibrillation	O
unrelated	O
to	O
myocardial	O
infarction	O
,	O
and	O
14	O
%	O
of	O
all	O
ventricular	other-medical
fibrillation	other-medical
resuscitations	other-medical
in	O
patients	O
under	O
the	O
age	O
of	O
40	O
.	O

The	O
degree	O
of	O
tolerance	O
is	O
more	O
pronounced	O
with	O
clonazepam	other-medical
than	O
with	O
chlordiazepoxide	other-medical
.	O

Lamivudine	other-medical
(	O
3TC	other-medical
)	O
significantly	O
inhibits	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	O
to	O
the	O
active	O
form	O
,	O
and	O
accordingly	O
the	O
drugs	O
should	O
not	O
be	O
administered	O
together	O
.	O

While	O
one	O
of	O
the	O
main	O
rationales	O
for	O
the	O
use	O
of	O
this	O
class	O
is	O
the	O
avoidance	O
of	O
a	O
persistent	O
dry	O
cough	O
and/or	O
angioedema	O
associated	O
with	O
ACE	other-medical
inhibitor	other-medical
therapy	O
,	O
rarely	O
they	O
may	O
still	O
occur	O
.	O

Since	O
the	O
1960s	O
,	O
when	O
she	O
first	O
joined	O
the	O
university	O
,	O
Wohl	O
specialized	O
in	O
the	O
respiratory	other-medical
diseases	O
of	O
children	O
and	O
was	O
a	O
leader	O
in	O
the	O
field	O
of	O
clinical	O
research	O
on	O
Cystic	O
fibrosis	O
.	O

These	O
findings	O
show	O
that	O
fluoxetine	other-medical
as	O
well	O
as	O
other	O
antidepressants	O
that	O
act	O
through	O
the	O
same	O
mechanisms	O
as	O
fluoxetine	other-medical
enhance	O
neurorecovery	O
and	O
neurotransmission	O
to	O
reduce	O
the	O
risk	O
of	O
depression	O
.	O

Small	O
,	O
asymptomatic	O
nodules	other-medical
are	O
common	O
,	O
and	O
often	O
go	O
unnoticed	O
.	O

As	O
the	O
number	O
of	O
opioid	other-medical
prescriptions	O
rose	O
,	O
drug	O
cartels	O
began	O
flooding	O
the	O
US	O
with	O
heroin	O
from	O
Mexico	O
.	O

The	O
Clinical	O
Pharmacogenetics	O
Implementation	O
Consortium	O
recommends	O
avoiding	O
amitriptyline	other-medical
in	O
patients	O
who	O
are	O
CYP2D6	O
ultrarapid	O
or	O
poor	O
metabolizers	O
,	O
due	O
to	O
the	O
risk	O
for	O
a	O
lack	O
of	O
efficacy	O
and	O
side	O
effects	O
,	O
respectively	O
.	O

Weight	O
loss	O
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
pirfenidone	other-medical
.	O

The	O
discovery	O
and	O
development	O
of	O
this	O
first	O
sulfonamide	other-medical
drug	O
opened	O
a	O
new	O
era	O
in	O
medicine	O
.	O

The	O
combination	O
of	O
paracetamol	other-medical
with	O
caffeine	other-medical
is	O
superior	O
to	O
paracetamol	other-medical
alone	O
for	O
the	O
treatment	O
of	O
common	O
pain	O
conditions	O
,	O
including	O
dental	O
pain	O
,	O
``	O
post	O
partum	O
''	O
pain	O
,	O
and	O
headache	O
.	O

Benzopyrone	other-medical
may	O
refer	O
to	O
either	O
of	O
two	O
ketone	O
derivatives	O
of	O
benzopyran	O
which	O
constitute	O
the	O
core	O
skeleton	O
of	O
many	O
flavonoid	O
compounds	O
:	O

Acyclovir	other-medical
,	O
favipiravir	other-medical
,	O
and	O
remdesivir	other-medical
have	O
been	O
assessed	O
as	O
potential	O
antivirals	O
against	O
Nipah	O
virus	O
.	O

Milloy	O
has	O
campaigned	O
against	O
the	O
1972	O
ban	O
on	O
non-public-health	O
uses	O
of	O
DDT	other-medical
in	O
the	O
United	O
States	O
and	O
in	O
favour	O
of	O
wider	O
use	O
of	O
DDT	other-medical
against	O
malaria	O
,	O
which	O
he	O
claims	O
could	O
be	O
largely	O
eliminated	O
if	O
DDT	other-medical
were	O
used	O
more	O
aggressively	O
.	O

The	O
Dependency	O
,	O
Emotional	O
,	O
Attachment	O
Programme	O
(	O
DEAP	O
)	O
is	O
another	O
abstinence	O
based	O
treatment	O
Acorn	other-medical
developed	O
which	O
incorporates	O
psychodynamic	O
therapy	O
,	O
Gestalt	other-medical
psychology	other-medical
,	other-medical
Cognitive	other-medical
behavioral	other-medical
therapy	other-medical
and	O
Rational	other-medical
Emotive	other-medical
Therapy	other-medical
in	O
a	O
12-	O
to	O
20-week	O
program	O
.	O

San	O
Antonio	O
's	O
South	O
Texas	O
Medical	O
Center	O
facilities	O
rank	O
sixth	O
in	O
clinical	other-medical
medicine	other-medical
research	other-medical
impact	O
in	O
the	O
United	O
States	O
.	O

The	O
anti-cancer	O
drug	O
imatinib	other-medical
has	O
recently	O
been	O
shown	O
to	O
reverse	O
the	O
graying	O
process	O
.	O

Several	O
popular	O
products	O
sold	O
by	O
SKF	O
contained	O
amphetamine	other-medical
,	O
including	O
Benzedrine	other-medical
pills	O
and	O
inhalers	O
,	O
Dexedrine	other-medical
pills	O
and	O
Dexamyl	other-medical
tablets	O
.	O

In	O
1996	O
,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
approved	O
Gemzar	other-medical
for	O
the	O
treatment	O
of	O
pancreatic	O
cancer	O
.	O

Cryotherapy	other-medical
may	O
be	O
used	O
to	O
treat	O
a	O
variety	O
of	O
tissue	O
lesions	O
.	O

But	O
even	O
years	O
of	O
psychoanalysis	other-medical
accomplished	O
little	O
,	O
if	O
anything	O
,	O
in	O
curing	O
premature	O
ejaculation	O
.	O

Like	O
NSAIDs	other-medical
and	O
unlike	O
opioid	O
analgesics	O
,	O
paracetamol	other-medical
has	O
not	O
been	O
found	O
to	O
cause	O
euphoria	O
or	O
alter	O
mood	O
although	O
recent	O
research	O
shows	O
some	O
evidence	O
that	O
paracetamol	other-medical
can	O
ease	O
psychological	O
pain	O
.	O

The	O
anesthetic	O
and	O
intoxicating	O
effects	O
of	O
ether	other-medical
have	O
made	O
it	O
a	O
recreational	O
drug	O
.	O

Another	O
patient	O
,	O
in	O
whom	O
POIS	O
was	O
suspected	O
to	O
be	O
caused	O
by	O
cytokine	O
release	O
,	O
was	O
successfully	O
treated	O
with	O
nonsteroidal	other-medical
anti-inflammatory	other-medical
drugs	other-medical
(	O
NSAIDs	other-medical
)	O
just	O
prior	O
to	O
and	O
for	O
a	O
day	O
or	O
two	O
after	O
ejaculation	O
.	O

In	O
an	O
early	O
report	O
on	O
inhibition	O
of	O
snake	O
venom	O
toxicities	O
,	O
Varespladib	other-medical
,	O
and	O
its	O
orally	other-medical
bioavailable	other-medical
prodrug	other-medical
methyl-varespladib	other-medical
(	O
LY333013	other-medical
)	O
showed	O
strong	O
inhibition	O
of	O
28	O
types	O
of	O
svPLA2s	O
from	O
six	O
continents	O
.	O

However	O
,	O
most	O
data	O
remain	O
proprietary	O
and	O
thus	O
reviews	O
on	O
the	O
expanded	O
clinical	O
potential	O
for	O
drugs	O
like	O
aprepitant	other-medical
range	O
from	O
optimistic	O
to	O
poor	O
.	O

As	O
a	O
pharmaceutical	O
drug	O
it	O
is	O
called	O
cholecalciferol	other-medical
(	O
USAN	other-medical
)	O
or	O
colecalciferol	other-medical
(	O
INN	other-medical
,	O
BAN	other-medical
)	O
.	O

A	O
single	O
,	O
modified	O
TEG	other-medical
assay	O
with	O
exogenous	O
tissue	other-medical
plasminogen	other-medical
activator	other-medical
(	O
tPA	other-medical
)	O
demonstrated	O
remarkable	O
efficiency	O
in	O
unmasking	O
patients	O
'	O
impending	O
risk	O
for	O
massive	O
transfusion	O
in	O
trauma	O
patients	O
.	O

The	O
Mexican	O
traveller	O
was	O
also	O
discharged	O
after	O
treatment	O
with	O
the	O
antiviral	O
drug	O
Tamiflu	other-medical
and	O
the	O
Centre	O
for	O
Health	O
Protection	O
confirmed	O
that	O
he	O
was	O
no	O
longer	O
carrying	O
the	O
virus	O
.	O

Trebananib	other-medical
and	O
tasquinimod	other-medical
are	O
other	O
angiogenesis	O
inhibitors	O
being	O
investigated	O
.	O

Guaifenesin	other-medical
is	O
used	O
to	O
try	O
to	O
help	O
with	O
coughing	O
up	O
thick	O
mucus	O
and	O
is	O
sometimes	O
combined	O
with	O
dextromethorphan	other-medical
,	O
an	O
antitussive	O
(	O
cough	other-medical
suppressant	other-medical
)	O
,	O
such	O
as	O
in	O
Mucinex	other-medical
DM	other-medical
or	O
Robitussin	other-medical
DM	other-medical
.	O

A	O
number	O
of	O
high-profile	O
infant	O
rapes	O
appeared	O
since	O
2001	O
(	O
including	O
the	O
fact	O
that	O
they	O
required	O
extensive	O
reconstructive	other-medical
surgery	other-medical
to	O
rebuild	O
urinary	O
,	O
genital	O
,	O
abdominal	O
,	O
or	O
tracheal	O
systems	O
)	O
.	O

While	O
Fisher	O
was	O
in	O
Chicago	O
filming	O
the	O
movie	O
,	O
she	O
choked	O
on	O
a	O
Brussels	O
sprout	O
;	O
Dan	O
Aykroyd	O
performed	O
the	O
Heimlich	other-medical
maneuver	other-medical
and	O
``	O
saved	O
my	O
life	O
''	O
.	O

Precious	O
Blood	O
Hospital	O
offers	O
specialist	O
outpatient	O
and	O
inpatient	O
services	O
in	O
General	other-medical
medicine	other-medical
,	O
Surgery	other-medical
,	O
Obstetrics	other-medical
and	O
Gynaecology	other-medical
,	O
Orthopaedics	other-medical
and	O
Ophthalmology	other-medical
.	O

They	O
are	O
rethinking	O
chemotherapy	other-medical
because	O
of	O
the	O
antiangiogenic	O
effects	O
of	O
low	O
dose	O
chemotherapy	other-medical
given	O
on	O
a	O
more	O
frequent	O
basis	O
than	O
conventional	O
chemotherapy	other-medical
.	O

Fentanyl	other-medical
intoxication	O
and	O
recent	O
methamphetamine	O
use	O
might	O
have	O
increased	O
the	O
likelihood	O
of	O
death	O
.	O

Fentanyl	other-medical
is	O
a	O
synthetic	O
opioid	O
in	O
the	O
phenylpiperidine	O
family	O
,	O
which	O
includes	O
sufentanil	other-medical
,	O
alfentanil	other-medical
,	O
remifentanil	other-medical
,	O
and	O
carfentanil	other-medical
.	O